APIM THERAPEUTICS COMPLETES PRIVATE PLACEMENT AND ENTERS PHASE-2 CLINICAL DEVELOPMENT
Trondheim, 18 May 2021 APIM Therapeutics AS (“APIM Therapeutics” or the “Company”), an oncology focused biotechnology company developing innovative anti-cancer treatments targeting stress responses in tumor cells, is pleased to announce the completion of a private placement directed towards existing and certain new investors in the Company (the “Private Placement”). “We are pleased to welcome 11 new investors to our existing strong shareholder base. The proceeds from this round put APIM Therapeutics in a strong position to advance the Company’s solid science to further clinical